The Care Capital team consists of professionals with experience
in all aspects of life science investment including drug development, regulatory
and commercial strategy, scientific expertise, operational management and
finance. The firm's partners have been responsible for the development,
management and launch of drugs having over $50 billion in peak sales and bring a
depth of experience and business relationships that provide tangible value to
our portfolio companies and investors.
Before joining Care Capital in 2002, Mr. Cabo was
Chief Financial Officer for KBL Healthcare Ventures where he had
full responsibility for the financial activities of the General,
Limited Partners and Venture Capital funds, overseeing all treasury
functions, budgeting and the maintenance of the partners capital
From 1999 to 2001, Mr. Cabo was a Director - High Yield Division at
CIBC World Markets, where he provided financial support to the High
Yield Private Equity Funds and 120 related corporate entities.
Previously, Mr. Cabo was Corporate Controller for Access America
Financial and a Senior Accountant at Kaufman, Rossin & Company, a
CPA firm in Miami, FL. He has also acted as Tax Consultant for Price
Waterhouse and Arthur Andersen & Co.
Mr. Cabo received his B.S. in Accounting from Manhattan College and
his M.B.A. from Rider University. He is a Certified Public
Accountant and a Member of the American Institute of Certified
Public Accountants and the New Jersey Society of Certified Public
Dr. Karabelas was Head of Healthcare and CEO of
Worldwide Pharmaceuticals for Novartis AG from 1998 until July 2000.
He had full responsibility for Novartis Pharma, Ciba Vision and
Generics representing $12 billion in annual sales. Included in these
responsibilities was strategic and operational leadership of R&D
with a budget in excess of $2 billion. Prior to joining Novartis,
Jerry was Executive Vice President of SmithKline Beecham responsible
for US operations, European operations, Regulatory, and Strategic
Marketing. He has been responsible for numerous pharmaceutical
product approvals and new product launches, including the launch of
four $1 billion products.
Jerry was the Founder and Chairman of the Novartis BioVenture Fund
from July 2000 until December 2001. In this role he invested
approximately $40 million in 14 portfolio companies.
Jerry holds a Ph.D. in Pharmacokinetics from the Massachusetts
College of Pharmacy. He is a member of the Visiting Committee for
Health Sciences and Technology at MIT. He is Chairman of SkyePharma
PLC and Human Genome Sciences, Inc., and is Chairman or a Director
of several Care Capital portfolio companies.
Before founding Care Capital, Mr. Leschly was Chief
Executive of SmithKline Beecham PLC ("SB") from 1994 to 2000. He
joined SB as Chairman of the Worldwide Pharmaceutical business in
1990 and was elected to the Board of Directors in 1990.
Before joining SB, Mr. Leschly served as President and COO, Squibb
Corporation. He joined Squibb in 1979 as Vice President, Commercial
Development and in 1984 he was elected Group Vice President and a
Member of the Board of Directors with responsibility for the
Worldwide Pharmaceuticals Products Group. Prior to this he worked
for seven years with Novo Nordisk, where he served as Executive Vice
President and President of the Pharmaceutical Division.
Mr. Leschly is a member of the Boards of Directors of the American
Express Company and the APM-Maersk Group.
Before his business career, Mr. Leschly made his name in
professional tennis, achieving the rank of 10th in the world in
Born in Denmark, Mr. Leschly received a Master of Science in
Pharmacy from the Copenhagen College of Pharmacy and a B.S. in
Business Administration from the Copenhagen School of Economics and
Prior to joining Care Capital, Mr. Markham was the
Vice Chairman of the Management Board and COO of Aventis. Previously
he was the CEO of Aventis Pharma, the CEO of Hoechst Marion Roussel,
and the President and COO of Marion Merrell Dow, Inc. and a member
of its board of directors.
From 1973 to 1993, Mr. Markham was associated with Merck & Co.,
Inc., culminating in his position as President and COO. Prior to
this role, Mr. Markham held a number of positions, starting as a
professional representative and then becoming district manager,
product manager and director, executive director and then VP of
Marketing for the Merck Sharp & Dohme Division. He later was
responsible for Merck’s European pharmaceutical business before
being named Senior Vice President of Merck & Co. and President of
the Merck Human Health Division, responsible for worldwide marketing
and sales of Merck’s pharmaceutical products.
Mr. Markham received a B.S. in Pharmacy and Pharmacal Sciences from
Purdue University and has served as a member of the Dean’s Advisory
Council of the university. He has also been awarded an honorary
Doctor of Science degree, the university’s highest honor for
Mr. Markham has been a member of the board of directors and
executive committee of the Pharmaceutical Research and Manufacturers
Association, a member of the Board of Trustees of the HealthCare
Institute of New Jersey, and a member of the board of directors of
Aventis Pasteur and of Commerce Bank of Kansas City.
Prior to joining Care Capital, Dr. Pellegrini was a
post-doctoral research fellow in the Department of Cell Biology at
Yale University, where he investigated the molecular basis of
neuronal signaling and receptor internalization. During his ten-year
tenure as an academic research scientist, Dr. Pellegrini published
original research in several leading peer-reviewed scientific
journals, including Nature, Cell and Neuron among others, and was
awarded a number of awards, including EMBO and Howard Hughes Medical
Dr. Pellegrini holds a Laurea in Chemistry, summa cum laude, from
the University of Padova, Italy, a Ph.D. in Biochemistry from the
Max-Planck-Institute for Brain Research in Frankfurt am Main,
Germany, and an M.B.A. with Honors from The Wharton School of the
University of Pennsylvania.
Mr. Ramsay co-founded Care Capital in 2001.
Previously, he was a private equity investor, initially with Morgan
Stanley Capital Partners and then as a
co-founder of the private equity business of Rhône Group.
Mr. Ramsay received an A.B. in Mathematics from Princeton University
and an M.B.A. from Stanford University.
Bob Seltzer joined Care Capital in 2005 and became a Partner
in 2010. Prior to Care Capital, Mr. Seltzer was a management consultant
with the Boston Consulting Group where he focused on the pharmaceutical industry,
identifying and analyzing strategic opportunities in R&D. Previously,
Mr. Seltzer performed financial analysis in GlaxoSmithKline's Deal Structuring
Group, and he co-founded and was President of the technology company Trenza Corp.
Prior to his business career, Mr. Seltzer was an accomplished chess player, winning
five US National titles for his age group and earning the title of Life National Master.
Mr. Seltzer holds a B.S. in Molecular Biophysics and Biochemistry from Yale University,
a Masters of Biotechnology from the University of Pennsylvania, and an MBA from The
Wharton School, where he was a Palmer Scholar.